Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…Abstract Number: 1716 • ACR Convergence 2022
The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice
Background/Purpose: Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for…Abstract Number: PP13 • ACR Convergence 2022
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…Abstract Number: 0357 • ACR Convergence 2022
Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Background/Purpose: Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil…Abstract Number: 0650 • ACR Convergence 2022
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…Abstract Number: 1717 • ACR Convergence 2022
Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli
Background/Purpose: Interleukin 23 (IL-23) is involved in the pathogenesis of systemic lupus erythematosus (SLE). IL-23 is elevated in the sera of patients with active SLE…Abstract Number: PP26 • ACR Convergence 2022
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…Abstract Number: 0066 • ACR Convergence 2022
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple…Abstract Number: 0358 • ACR Convergence 2022
Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
Background/Purpose: The AURORA 1 study demonstrated that addition of voclosporin to MMF and low-dose steroids significantly increased complete renal response rates at 52 weeks, with…Abstract Number: 0651 • ACR Convergence 2022
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Background/Purpose: The pathogenesis of lupus nephritis (LN) is incompletely understood stalling progress and resulting in suboptimal patient outcomes. We previously identified a novel inflammatory dendritic…Abstract Number: 1376 • ACR Convergence 2022
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
Background/Purpose: Eculizumab is a monoclonal antibody that prevents the cleavage of C5, which inhibits the formation of the terminal complement complex. It is approved in…Abstract Number: 1718 • ACR Convergence 2022
Parenchymal INFγ Response Regulates Murine Lupus Nephritis
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE. Interstitial infiltrates, specifically T cells, are major predictors of disease outcomes. We recently…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 37
- Next Page »